Sojung Kim

Sojung Kim

Auto-generated profile, based on publicly available information

Sojung Kim

Division of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
Dong Jin KimDong Jin Kim
Dong Jin Kim
JSJeong Ho Song
Jeong Ho Song
JPJi-Hyeon Park
Ji-Hyeon Park
SKSojung Kim
Sojung Kim
SPSin Hye Park
Sin Hye Park
TAThe Information Committee of the Korean Gastric Cancer Association
The Information Committee of the Korean Gastric Cancer Association
Kim DJ, et al. J Gastric Cancer. 2024 Dec;25:e8. https://doi.org/10.5230/jgc.2025.25.e8

11 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CJChul-Hyo Jeon
Chul-Hyo Jeon
SKSo-Jung Kim
So-Jung Kim
HLHan Hong Lee
Han Hong Lee
KSKyo-Young Song
Kyo-Young Song
HSHo Seok Seo
Ho Seok Seo
Radical gastrectomy is essential for gastric cancer treatment. While guidelines advise dissecting at least 16 lymph nodes, some research suggests over 30 nodes might be beneficial. This study assessed ICG-guided robotic gastrectomy’s effectiveness in thorough lymph node dissection. We analyzed data from 393 stage II or III gastric cancer patients treated at Seoul St. Mary’s Hospital from 2016–2022. Patients were categorized into conventional laparoscopy (G1, n = 288), ICG-guided laparoscopy (G2, n = 61), and ICG-guided robotic surgery (G3, n = 44). Among 391 patients, 308 (78.4%) achieved proper lymphadenectomy. The ICG-robotic group (G3) showed the highest success rate at 90.9%. ICG-guided robotic surgery was a significant predictor for achieving proper lymphadenectomy, with an odds ratio of 3.151. In conclusion, ICG-robotic gastrectomy improves lymphadenectomy outcomes in selected gastric cancer cases, indicating a promising surgical approach for the future.

21 September 2022 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
SKSo Jung Kim
So Jung Kim
CJChul Hyo Jeon
Chul Hyo Jeon
HLHan Hong Lee
Han Hong Lee
KSKyo Young Song
Kyo Young Song
HSHo Seok Seo
Ho Seok Seo

1 September 2017 in Nuklearmedizin-Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
SSSeunghyeon Shin
Seunghyeon Shin
KKKeunyoung Kim
Keunyoung Kim
BKBum-soo Kim
Bum-soo Kim
SKSeong-Jang Kim
Seong-Jang Kim
WCWonjae Cha
Wonjae Cha
IKIn Joo Kim
In Joo Kim
Purpose: We assessed patient discomfort and identified factors predictive of discomfort while receiving radioactive iodine (RAI) ablation.Methods: Between August 2015 and April 2016, 52 patients with differentiated thyroid cancer were enrolled in this study. All patients received recombinant human thyroid stimulating hormone (rhTSH) aided RAI ablation using 3.7 GBq or 5.55 GBq of RAI. Discomfort during their stay for RAI ablation was evaluated using a symptom questionnaire. We analyzed the relationship between the patient’s clinical data and the scores for the 15 items of the symptom questionnaire. We compared scores of questionnaires between male and female, under 45 years old and 45 and older, RAI activity of 3.7 GBq and 5.55 GBq. Also, scores of daily questionnaires were tested for differences.Results: Most patients did not have severe discomfort, but some patients had mild discomfort during their stay for RAI ablation, despite using rhTSH. Important determinants of discomfort were sex and age. Female patients reported more symptoms of fatigue, facial edema, cold intolerance, and nausea. Older patients (45 and older) complained of insomnia more often. However, the dose of RAI ablation (3.7 GBq vs 5.55 GBq) did not affect the scores of questionnaires.Conclusions: Sex and age were important predictors of patient’s discomfort during RAI ablation. Clinicians need to explain more about treatment and predicted discomforts to such patients before RAI ablation. Zweck: Wir untersuchten unter ablativer Ra- dioiodtherapie (RIT) auftretende Beschwerden und identifizierten prognostische Faktoren für Beschwerden bei den Patienten.Methoden: Von August 2015 bis April 2016 wurden 52 Patienten mit differenziertem Schilddrüsenkarzinom in die Studie aufgenommen. Alle Patienten erhielten eine durch rekombinantes humanes Thyreoidea-stimulierendes Hormon (rhTSH) gestützte ablative RIT mit 3,7 GBq oder 5,55 GBq. Die Beschwerden während des Aufenthaltes wegen der RIT wurden anhand eines Symptom-Fragebogens evaluiert. Wir analysierten den Zusammenhang zwischen den klinischen Daten der Patienten und den Scores in den 15 Items des Fragebogens. Die Fragebogen-Scores wurden wie folgt verglichen: Männer vs. Frauen, < 45-jährige vs. ≥ 45-jährige sowie RIT-Aktivität von 3,7 GBq vs. 5,55 GBq. Außerdem wurden die Scores der täglichen Fragebögen auf Unterschiede getestet.Ergebnisse: Die meisten Patienten hatten keine wesentlichen Beschwerden, bei manchen traten im Laufe des RIT- Aufenthaltes trotz rhTSH-Gabe leichte Beschwerden auf. Wichtige Determinanten für Beschwerden waren das Alter und das Geschlecht. Patientinnen berichteten häufiger über Symptome wie Müdigkeit, Gesichtsödem, Kälteunverträglichkeit und Übelkeit. Ältere Patienten (≥ 45 Jahre) klagten häufiger über Schlaflosigkeit. Die Dosis der ablativen RIT (3,7 GBq vs. 5,55 GBq) hatte jedoch keinen Einfluss auf die Fragebogen-Scores.Schlussfolgerungen: Geschlecht und Alter waren wichtige Prädiktoren für Beschwerden unter einer ablativen RIT. Daher sollten Ärzte die Patienten vor einer ablativen RIT besser über die Behandlung und vorhersehbare Beschwerden aufklären. * Kyoungjune Pak and So Jung Kim contributed equally to this work as first authors.

1 January 2021 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
SKSo Jung Kim
So Jung Kim
CJChul-Hyo Jeon
Chul-Hyo Jeon
YJYoon Ju Jung
Yoon Ju Jung
HSHo Seok Seo
Ho Seok Seo
HLHan Hong Lee
Han Hong Lee
KSKyo Young Song
Kyo Young Song
Kim SJ, et al. J Gastric Cancer. 2021 Sep;21(3):308-318. https://doi.org/10.5230/jgc.2021.21.e30

1 January 2023 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
HSHo Seok Seo
Ho Seok Seo
SKSojung Kim
Sojung Kim
KSKyo Young Song
Kyo Young Song
HLHan Hong Lee
Han Hong Lee
Seo HS, et al. J Gastric Cancer. 2023 Jul;23:e26. https://doi.org/10.5230/jgc.2023.23.e26